ScyFIX uses targeted micro-current energy to address the Dry form of Macular Degeneration (AMD) and Retinitis Pigmentosa (RP). ScyFIX has completed two human Pilot clinical trials for RP and AMD that demonstrated safety, stability and improvements in visual acuity, fields, contrast sensitivity and quality of life. Some patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles; none of these day-to-day activities were possible for these patients before using the ScyFIX.
|
